All News
Efficacy and Safety of Xeligekimab in AS
Dr. Adela Castro reports on abstract OP0102 at the EULAR 2025 meeting in Barcelona, Spain
https://t.co/xpzeV0oZOr https://t.co/mEYnAFsYQI
Dr. John Cush RheumNow ( View Tweet)
2025 EULAR/ACR Risk Stratification Criteria for At-Risk Arthralgia
A collaborative EULAR/ACR expert panel has established criteria for arthralgia patients at risk (clinically suspect arthralgia) to progress to chronic rheumatoid arthritis (RA). Risk stratification of CSA https://t.co/STmuNO3c2Z
Dr. John Cush RheumNow ( View Tweet)
⌛️ Diagnostic delay in #SpA: Better with time?
🔹️Data from the @Official_ASAS
Study
🔹️4339 patients
🔹️Delay decreased over time
🔹️Same trends across world regions & across Human Development Index categories
POS0908 #EULAR2025
@RheumNow https://t.co/Y9gxQDV9KJ
Nelly ZIADE 🍀 Nellziade ( View Tweet)
EULAR Points to consider for the definition of D2M and TR #Psoriatic_Arthritis
Presented by Dr Helena Marzo-Ortega at #EULAR2025
@RheumNow https://t.co/3LsJvSiXJV
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Sometimes you hear:
“PMR dose steroids don’t really matter”
Errrrr…
(You wouldn’t accept this steroid exposure in any other disease. Never)
#EULAR2025 POS0139 @RheumNow https://t.co/o6w2RpaGBj
David Liew drdavidliew ( View Tweet)
The new (provisional) 2025 EULAR/ACR classification criteria for anti-synthetase syndrome
#EULAR2025 @RheumNow https://t.co/X6VjcN8XZe
Links:
David Liew drdavidliew ( View Tweet)
@RheumNow EULAR haemochromatosis arthropathy classification criteria
Patrick Kiely: please photograph this and take it back to your communities
Patient association lead comes to the microphone, and thanks them for making be seen. 🥲
#EULAR2025 @RheumNow https://t.co/9bqdV0fuPk
David Liew drdavidliew ( View Tweet)
#WIN in systemic sclerosis (SSc):
-Ongoing trials now targeting multiple pathways.
-CONQUEST platform may reshape research in Ssc and other autoimmune diseases.
-Revised CRISS could replace single organ endpoints for approval.
#EULAR2025
@RheumNow https://t.co/kxSeFb5lAU
Links:
Adela Castro AdelaCastro222 ( View Tweet)
+RCT in #pSjD #Sjogrens #Disease
#Leflunomide + #hydroxychloroquine
Vs #PBO
2nd study to show this - same group
need to know
▶️what pt to use this in
▶️is there diff organ improvements
⬆️#ESSDAI
⬇️RF ⬇️Ig’s
Easy to prescribe
?early, mild dx
#EULAR2025 @RheumNow @eular_org https://t.co/JE0VyFRXc6
Links:
Janet Pope Janetbirdope ( View Tweet)
#EULAR2025 Based on the updated EULAR Guidelines on #lupus nephritis, should all patients receive early Combination therapies for remission induction? @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR vs #ACR #RA #recommendations
Do you agree that #ERA pts should receive #glucocorticoids
@RheumNow #EULAR2025
@eular_org
Janet Pope Janetbirdope ( View Tweet)
#EULAR2025 Abstr#OP0204 Limitations of #SLE Damage Index (SDI): outdated items definition, missing item & unclear use in children. Revised SDI (SLICC-ACR-LFA) via data-driven and expert patient-doctor consensus is underway. Next steps: validation and including weighting @RheumNow https://t.co/K5rPgXBPrj
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
ARIAA study: longer-term data now
High-risk ACPA+ clinically suspect arthralgias
abatacept for 6mo, then stop altogether
Really impressive long-term effect
also noting success of APIPPRA, abatacept flicks off some very early RA, at least for a while
#EULAR2025 OP0325 @RheumNow https://t.co/AeRrUKPPiK https://t.co/jtynyD0ioO
Links:
David Liew drdavidliew ( View Tweet)
Highlights @eular_org #EULAR2025
RCTs + in CTD/RA #ILD w #PPF LB0003
Lots of #CAR-T studies in #SARDs
Lots of bDMARDs in
#SLE
#APS
#IgG4
#SjD
Neurostimulation 👇
⬇️inflammation
⬇️pain
#RA
#fibromyalgia
#EULAR2025 @RheumNow @eular_org
Janet Pope Janetbirdope ( View Tweet)
EULAR FMF recommendations 2025:
still emphasis on colchicine adherence to maximal dose
+/- bDMARDs if needed for control
+/- csDMARDs for residual chronic MSK involvement
new: consider tapering bDMARD if remission >6mo
See the treatment algorithm below⬇️
#EULAR2025 @RheumNow https://t.co/Hy6DOKzfUL
Links:
David Liew drdavidliew ( View Tweet)
Despite the evolution of anti-synthetase antibodies, there’s a clear need for better ways to define the disease.
Enter the ACR/EULAR CLASS initiative - classification criteria for anti-synthetase syndrome
⬇️ see the next tweet
#EULAR2025 @RheumNow https://t.co/Z3rPOt1vlx
Links:
David Liew drdavidliew ( View Tweet)
FMF #Recommendations
During attack:
🔺️No use of increasing Colchicine
🔺️No use for corticosteroids and opioid
🔺️Use NSAIDs
#EULAR2025
@RheumNow https://t.co/jJjWJra7yr
Nelly ZIADE 🍀 Nellziade ( View Tweet)
EULAR/ACR Classification Criteria for #ASyS, the new acronym of Antisynthetase Syndrome
🔺️Do not apply if patient is positive for other antibodies like SSA
#EULAR2025
@RheumNow https://t.co/AD5tTipBtt
Nelly ZIADE 🍀 Nellziade ( View Tweet)
FMF #Recommendations
#Colchicine can be fatal
🔺️Monitor regularly
#EULAR2025
@RheumNow https://t.co/VJZYPaBrvE
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Why do people not respond to psoriatic arthritis therapies?
#EULAR2025 @RheumNow https://t.co/VGLN0R3TyY
David Liew drdavidliew ( View Tweet)
